Department of Microbiology and the Institute for Genomic Biology, University of Illinois, Urbana, IL, USA.
Gut Microbes. 2010 Nov-Dec;1(6):373-8. doi: 10.4161/gmic.1.6.13572.
Chronic infection of the human stomach by Helicobacter pylori is an important risk factor for gastric cancer. H. pylori produces a cache of virulence factors that promote colonization and persistence, which, in turn, contributes to a robust inflammatory response at the host-pathogen interface. Recently, we reported that H. pylori activates the abundant nuclear regulator poly(ADP-ribose) polymerase (PARP)-1, resulting in the production of the catabolite poly(ADP-ribose) (PAR). PARP-1 is emerging as a key player in establishing homeostasis at the host-pathogen interface. In this article, we summarize the discovery of H. pylori-dependent PARP-1 activation, and discuss potential roles for PARP-1 in H. pylori-mediated gastric disease. In light of the remarkable successes that have reported for treating inflammatory disorders and cancers with PARP-1 inhibitors, we discuss the prospects of targeting PARP-1 for treatment of H. pylori-associated gastric disease.
人胃内幽门螺杆菌的慢性感染是胃癌的一个重要危险因素。幽门螺杆菌产生了一系列毒力因子,促进定植和持续存在,进而导致宿主-病原体界面的强烈炎症反应。最近,我们报道幽门螺杆菌激活了丰富的核调节剂多聚(ADP-核糖)聚合酶(PARP)-1,导致代谢产物多聚(ADP-核糖)(PAR)的产生。PARP-1 正在成为在宿主-病原体界面建立动态平衡的关键参与者。在本文中,我们总结了幽门螺杆菌依赖性 PARP-1 激活的发现,并讨论了 PARP-1 在幽门螺杆菌介导的胃部疾病中的潜在作用。鉴于 PARP-1 抑制剂在治疗炎症性疾病和癌症方面取得的显著成功,我们讨论了针对 PARP-1 治疗幽门螺杆菌相关胃部疾病的前景。